Immatics (IMTX) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Immatics (IMTX) is set to report its Q1 2025 earnings on August 12, expecting a loss of ($0.38) per share with projected revenue of $13.05 million.
• After a recent earnings report in May, where Immatics beat expectations with revenue of $20.12 million, analysts predict the company will continue to experience a negative EPS trend for the current and next fiscal years.
• Institutional investors hold 64.41% of Immatics stock, with Bank of America recently increasing its position by 166%, signaling growing confidence in the company.

Immatics (NASDAQ:IMTX - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Immatics to post earnings of ($0.38) per share and revenue of $13.05 million for the quarter.

Immatics (NASDAQ:IMTX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. The business had revenue of $20.12 million during the quarter, compared to analyst estimates of $14.92 million. Immatics had a negative return on equity of 4.52% and a negative net margin of 14.73%. On average, analysts expect Immatics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immatics Price Performance

NASDAQ:IMTX traded down $0.05 during trading hours on Thursday, reaching $6.29. The company's stock had a trading volume of 111,818 shares, compared to its average volume of 758,883. The company has a market cap of $764.55 million, a price-to-earnings ratio of -37.00 and a beta of 0.93. The business's 50-day moving average is $5.97 and its 200-day moving average is $5.16. Immatics has a one year low of $3.30 and a one year high of $13.09.

Analysts Set New Price Targets

IMTX has been the topic of a number of research reports. Wall Street Zen cut Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft began coverage on Immatics in a research report on Wednesday, May 28th. They set a "buy" rating and a $10.00 price target on the stock. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $14.67.

Institutional Investors Weigh In On Immatics

An institutional investor recently raised its position in Immatics stock. Bank of America Corp DE boosted its stake in shares of Immatics N.V. (NASDAQ:IMTX - Free Report) by 166.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,575 shares of the company's stock after purchasing an additional 2,231 shares during the period. Bank of America Corp DE's holdings in Immatics were worth $25,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 64.41% of the company's stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.